Gynecomastia: An update

Endocrinologist

Volumn 16, Issue 2, 2006, Pages 109-115

  Pearlman, Gwen ^a   Carlson, Harold E ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Gynecomastia; Hypogonadism; Male breast cancer; Tamoxifen

Indexed keywords

AMIODARONE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; ANTIRETROVIRUS AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHORIONIC GONADOTROPIN; CIMETIDINE; CYTOTOXIC AGENT; DANAZOL; DIETHYLSTILBESTROL; EFAVIRENZ; ESTROGEN DERIVATIVE; FLUTAMIDE; ISONIAZID; KETOCONAZOLE; LEUPRORELIN; METRONIDAZOLE; PROTEINASE INHIBITOR; RALOXIFENE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEX HORMONE; SPIRONOLACTONE; STAVUDINE; TAMOXIFEN; UNINDEXED DRUG;

ADRENAL METASTASIS; ADRENAL TUMOR; AGING; BREAST AUGMENTATION; BREAST CANCER; BREAST DISEASE; CHRONIC KIDNEY FAILURE; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; ENDOCRINE DISEASE; ERYTHEMA; GYNECOMASTIA; HEALTH PRACTITIONER; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOGONADISM; LEYDIG CELL TUMOR; LIVER CIRRHOSIS; MEDICAL ASSESSMENT; PAIN; PHYSICAL EXAMINATION; PREVALENCE; PROSTATE CANCER; PUBERTY; RADIATION DOSE; REFEEDING SYNDROME; REVIEW; SKIN CANCER; SKIN IRRITATION; THYROTOXICOSIS;

EID: 33748483628     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000205637.20746.10     Document Type: Review

References (73)

1. Hassan MO, Olaizola MY. Ultrastructural observations on gynecomastia. Arch Pathol Lab Med. 1979;103:624-630.
2. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48:338-340.
3. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol. 1994;21:579-587.
4. Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984;77:633-638.
5. Braunstein GD. Aromatase and gynecomastia. Endocrine-Related Cancer. 1999;6:315-324.
6. Carlson HE. Gynecomastia: pathogenesis and therapy. The Endocrinologist. 1991;1:337-342.
7. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynecomastia. J Pathol. 1993;170:37-43.
8. Sasano H, Kimura M, Shizawa S, et al. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81:3063-3067.
9. Calzada L, Torrs-Calleja J, Martinez JM, et al. Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. Life Sci. 2001;69:1465-1469.
10. Parmar H, Cunha GR. Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocrine-Related Cancer. 2004;11:437-458.
11. Szelei J, Jimenez J, Soto AM, et al. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406-1412.
12. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10:292-298.
13. Carlson HE, Kane P, Lei ZM, et al. Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. J Clin Endocrinol Metab. 2004;89:4119-4123.
14. Bird J, Li X, Lei ZM, et al. Luteinizing hormone and human chorionic gonadotropin decrease type 2 5α-reductase and androgen receptor protein levels in women's skin. J Clin Endocrinol Metab. 1998;83:1776-1782.
15. Ruen W, Monaco ME, Kleinberg DL. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-1 action. Endocrinology. 2005;146:1170-1178.
16. Nomura K, Suzuki H, Saji M, et al. High serum progesterone in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab. 1988;66:230-232.
17. Farthing MJG, Green JRB, Edwards CRW, et al. Progesterone, prolactin, and gynecomastia in men with liver disease. Gut. 1982;23:276-279.
18. Kanhai RCJ, Hage JJ, VanDiest PJ, et al. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. Am J Surg Pathol. 2000;24:74-80.
19. Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab. 1998;83:1348-1357.
20. Binder G, Iliev DI, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab. 2005;90:484-492.
21. Young J, Bulun SE, Agarwal V, et al. Aromatase expression in a feminizing adrenocortical tumor. J Clin Endocrinol Metab. 1996;81:3173-3176.
22. Gabrilove JL, Sharma DC, Wotiz HH, et al. Feminizing adrenal cortical tumors in the male: a review of 52 cases including a case report. Medicine. 1965;44:37-79.
23. Gabrilove JL, Nicolis GL, Mitty HA, et al. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer. 1975;35:1184-1202.
24. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-731.
25. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol. 2004;60:653-670.
26. Couillard C, Gagnon J, Bergeron J, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE family study. J Clin Endocrinol Metab. 2000;85:1026-1031.
27. Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynecomastia. Clin Endocrinol. 1979;11:505-526.
28. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994;78:744-752.
29. Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol. 1993;39:417-425.
30. Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001;38:596-607.
31. Jacobs EC. Effects of starvation on sex hormones in the male. J Clin Endocrinol. 1948;8:227-232.
32. Handelsman D, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am. 1993;22:145-160.
33. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic disease. Eur J Endocrinol. 2005;152:501-513.
34. Schmitt GW, Shehadeh I, Sawin CT. Transient gynecomastia in chronic renal failure during chronic intermittent hemodialysis. Ann Intern Med. 1968;69:73-79.
35. Cavanaugh J, Niewohner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med. 1990;150:563-565.
36. Chopra IJ, Tulchinsky D. Status of estrogen-androgen balance in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab. 1974;38:269-277.
37. Becker KL, Winnacker JL, Matthews MJ, et al. Gynecomastia and hyperthyroidism. An endocrine and histological investigation. J Clin Endocrinol. 1968;28:277-285.
38. Southren AL, Olivo J, Gordon GG, et al. The conversion of androgens to estrogens in hyperthyroidism. J Clin Endocrinol Metab. 1974;38:207-214.
39. Ford HC, Cooke RR, Keightley EA, et al. Serum levels of free and bound testosterone in hyperthyroidism. Clin Endocrinol. 1992;36:187-192.
40. Piroth L, Grappin M, Petit JM, et al. Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis. 2001;33:559-560.
41. Caso JAA, Prieto JM, Casas E, et al. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS. 2001;15:1447-1448.
42. Biglia A, Blanco JL, Martinez E, et al. Gynecomastia among HIVinfected patients is associated with hypogonadism: a case-control study. Clin Infect Dis. 2004;39:1514-1519.
43. Strub C, Kaufmann GR, Flepp M, et al. Gynecomastia and potent antiretroviral therapy. AIDS. 2004;18:1347-1349.
44. Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immun Defic Syndr. 2004;35:99-102.
45. Qazi NA, Morlese JF, King DM, et al. Gynecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis. AIDS. 2002;16:506-507.
46. Carlson HE. Gynecomastia. N Engl J Med. 1980;303:795-799.
47. Giordano S. A review of the diagnosis and management of male breast cancer. The Oncologist. 2005;10:471-479.
48. Hunfeld K-P, Bässler R, Kronsbein H. 'Diabetic mastopathy' in the male breast - a special type of gynecomastia. Pathol Res Pract. 1997;193:197-205.
49. Ely KA, Tse G, Simpson JF, et al. Diabetic mastopathy. A clinicopathologic review. Am J Clin Pathol. 2000;113:541-545.
50. Weinstein SP, Conant EF, Orel SG, et al. Diabetic mastopathy in men: imaging findings in two patients. Radiology. 2001;219:797-799.
51. Bayer U, Horn L-C, Schulz H-G. Bilateral, tumorlike diabetic mastopathy - progression and regression of the disease during 5-year follow up. Eur J Radiol. 1998;26:248-253.
52. Evans GFF, Anthony T, Appelbaum AH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181:96-100.
53. Hanavadi S, Monypenny IJ, Mansel RE. Is mammography overused in male patients? The Breast. 2006;15:123-6.
54. Özdemir A, Öznur ĎĎ, Vural G, et al. TL-201 scintigraphy, mammography and ultrasonography in the evaluation of palpable and nonpalpable breast lesions: a correlative study. Eur J Radiol. 1997;24:145-154.
55. Ting ACW, Chow LWC, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg. 2000;66:38-40.
56. Khan HN, Rampaul R, Blamey RW. Management of physiological gynecomastia with tamoxifen. The Breast. 2004;13:61-65.
57. Hanavadi S, Banerjee D, Monypenny IJ, et al. The role of tamoxifen in the management of gynecomastia. The Breast. In press.
58. Lawrence SE, Faught KA, Vethamuthu J, et al. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145:71-76.
59. Li C, Lee F, Hwang S, et al. Treatment of mastalgia with tamoxifen in male patients with cirrhosis: a randomized crossover study. Am J Gastroenterol. 2000;95:1051-1055.
60. Saltzstein D, Sieber P, Morris T, et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005;8:75-83.
61. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology. 1997;50:929-933.
62. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology. 2000;56:713-720.
63. Sanchez A, Carretto H, Parma R. Treatment of gynecomastia with raloxifene. BMJ. 2003;
64. Rapid response to Khan HN, Blamey RW. Endocrine treatment of physiological gynecomastia. BMJ. 2003;327:301-302. Available at: http://bmj.bmjjournals.com/cgi/eletters/327/7410/301. Accessed November 26, 2005.
65. Riepe FG, Baus I, Wiest S, et al. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Hormone Res. 2004;62:113-118.
66. Plourde PV, Reiter EO, Jou H-C, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo- controlled trial. J Clin Endocrinol Metab. 2004;89:4428-4433.
67. Widmark A, Fossa SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 2003;61:145-151.
68. Tyrrell CJ, Payne H, Tammela TLJ, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys. 2004;60:476-483.
69. Van Poppel H, Tyrrell CJ, Haustermans K, et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol. 2005;47:587-592.
70. Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol. 2003;4:30-36.
71. Matarasso A. Suction mammoplasty: the use of suction lipectomy to reduce large breasts. Plast Reconstr Surg. 2000;105:2604-2607.
72. Hodgson EL, Fruhstorfer BH, Malata CM. Ultrasonic liposuction in the treatment of gynecomastia. Plast Reconstr Surg. 2005;116:646-653.
73. Thione A, Valdatta L, Gottardi A. A modified inverted omega incision for surgical treatment of gynecomastia. Ann Plast Surg. 2005;55:437.